Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced a major step forward in the development of its lead cancer therapy candidate, ONC010. The company has successfully completed key manufacturing and preclinical milestones, setting the stage for human clinical trials. This progress is particularly significant in the field of oncology, where DNA Damage Response (DDR) inhibition is emerging as a promising strategy to combat cancer's ability to repair damage caused by treatments.
ONC010 is designed to inhibit Polynucleotide Kinase Phosphatase (PNKP), an enzyme involved in DNA repair. By blocking PNKP, the therapy aims to make cancer cells more susceptible to DNA-damaging agents, potentially enhancing the effectiveness of existing treatments. The candidate utilizes a nanoparticle delivery system to target the small-molecule inhibitor specifically to cancer cells.
The company's latest update reveals that a 300-gram development batch of ONC010's active ingredient achieved approximately 99.3% purity. This high level of purity is crucial for ensuring safety and efficacy in future clinical use. Additionally, Onco-Innovations identified a non-tin catalyst that could improve impurity control in polymer manufacturing, a key component of the nanoparticle delivery system. This innovation may lead to more consistent and scalable production processes.
In terms of regulatory strategy, Onco-Innovations is building an Australian pathway for a potential First-in-Human study. The company plans to advance bioanalytical, metabolism, ADME (absorption, distribution, metabolism, and excretion), toxicology, biodistribution, and regulatory preparation during the second half of 2026. These activities are essential for filing a clinical trial application and initiating human trials.
The advancement of ONC010 is noteworthy because DDR inhibitors represent a growing area of cancer research. Traditional therapies like chemotherapy and radiation work by causing DNA damage in cancer cells, but cells can repair this damage and survive. By inhibiting PNKP, ONC010 could disable a key repair mechanism, potentially making cancer cells more vulnerable to treatment. This approach may offer new options for patients with cancers that are resistant to current therapies.
The successful manufacturing of the API at high purity is a critical milestone that de-risks the development process. It ensures that the drug substance can be produced consistently and meets quality standards for clinical trials. The identification of a non-tin catalyst also addresses potential toxicity concerns, as tin-based catalysts might be undesirable in pharmaceutical manufacturing.
Onco-Innovations' focus on an Australian regulatory pathway is strategic. Australia is known for its efficient clinical trial approval processes and high-quality research infrastructure. This could enable the company to initiate human studies more quickly than in other jurisdictions, accelerating the development timeline.
While ONC010 is still in the preclinical stage, these developments position the company to advance toward clinical trials. For patients and the oncology community, this represents a potential new therapeutic option that could improve outcomes by enhancing the efficacy of existing DNA-damaging treatments. For investors and industry observers, the progress underscores the potential of DDR inhibition as a viable approach in cancer therapy.
The announcement builds on previously disclosed information, and more details are available in the company's newsroom at ibn.fm/ONNVF. As Onco-Innovations continues to develop ONC010, the company is taking steps to address one of the fundamental challenges in oncology: overcoming cancer's ability to repair DNA damage. With these milestones, ONC010 moves closer to becoming a potential medicine that could benefit patients in need.
